Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare
A, part 1		
A, part 2(i)		
A, part 2(ii)		
A, part 2(iii)		
B (i)		
B(ii)	X	
C		
D		
E		X
F		X
G		X

(Please mark the appropriate box(es) for each measure, with a tick.)

Date: **April 4, 2008**

State Party to the Convention: **Czech Republic**

Form A, part 1

Exchange of data on research centres and laboratories [1] - # 1

1. **Name(s) of facility** [2]
   Microbiological Laboratory BSL-3

2. **Responsible public or private organization or company**
   Veterinary Research Institute

3. **Location and postal address**
   Hudcova 70, 621 32 Brno, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Ministry of Agriculture

5. **Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BL 3 (1 unit; total area approx. 100 m^2)

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Microbiological laboratory BSL 3 is designed and provided for work with Risk Group 3 microorganisms and with large volumes or high concentrations of Risk Group 2 microorganisms that pose an increased risk of aerosol spread.

---

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual or equivalent

Exchange of data on research centres and laboratories [1] - # 2

1. **Name(s) of facility** [2]
   Institute of Molecular Pathology (IMP) and Centre of Advanced Studies (CAS)

2. **Responsible public or private organization or company**
   University of Defence (the Ministry of Defence)

3. **Location and postal address**
   Institute of Molecular Pathology and Centre of Advanced Studies, Faculty of Military Health Sciences
   Exnárova 538, 500 01 Hradec Kralove

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Projects wholly financed MoD: Zamer ZHN2 (virulence factors study), BojAgens (Virulent factors of *Francisella tularensis*; host-pathogen interaction), Daldet III (System purposed for stand-off detection and identification of the CBA to timely warn the units against a chemical or biological attack) and Managment (BW crisis situation prediction)
   Project financed GA of Czech Rep.: Projekt 310/07/0226 (host-pathogen interaction of *Francisella tularensis*)

5. **Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**

   BL 3

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**

   Cultivation of microbes for proteomic studies.
   Cultivation of microbes for *in vivo* infection intended for the study of tularemia.
   Cultivation of microbes for *in vitro* infection intended for study of microbe – host cells interaction.

---

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

National biological defence research and development programme Declaration

Is there a national programme to conduct biological defense research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such a programme would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of the programme.

National biological defence research and development programme

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?
Institute of Molecular Pathology, FMMS, MoD, Hradec Kralove

2. Where is it located (include both address and geographical location)?
Trebesska 1575, 500 01 Hradec Kralove, Czech Rep.

3. Floor area of laboratory areas by containment level:

BL2 64 (sqM)

BL3 26 (sqM)

BL4 0 (sqM)

Total laboratory floor area 180 (sqM)

4. The organizational structure of each facility.

(I) Total number of personnel 27

(ii) Division of personnel:

Military	3
Civilian	24

(iii) Division of personnel by category:

Scientists	20
Engineers	0
Technicians	5
Administration and support staff	2

(iv) List the scientific disciplines represented in the scientific/ engineering staff.
Immunology, cell biology, molecular biology, bioinformatics, analytical chemistry

(v) Are contractor staff working in the facility? If so, provide an approximate number.
NO

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?
Staff salary - Ministry of Defence
Scientific activity according to projects

(vii) What are the funding levels for the following programme areas:

Research	YES
Development	-
Test and evaluation	-

(viii) Briefly describe the publication policy of the facility:

Results are published in international and national scientific and military journals.

(ix) Provide a list of publicly-available papers and reports resulting from the work during the previous 12 months. (To include authors, titles and full references.)

Eyer L., Pantucek R., Zdrahal Z., Konecna H., Ruzickova V., Hernychova L.: Structural protein analysis of the polyvalent staphylococcal bacteriophage 812, Proteomics, 2007, Wiley-VCH Verlag GmbH Co.&KGaA, Vol. 7, Iss. 64, p.72

Skultety L., Hernychova L., Bereghazyova E., Slaba K.,Toman R.: Detection of specificspectral markers of *Coxiella burnetii* isolates by MALDI-TOF mass spectrometry, Acta virologica, 2007, AEPress Ltd.,Vol. 51, Iss. 55, p. 58

Vavrova j., Janovska S., Rezacova M., Hernychova L., Ticha Z., Vokurkova D., Zaskodova D., Lukasova E.: Proteomics analysis of MOLT-4 cell treated by valporic acid, Mol. Cell Biochem., 2007, Vol. 7, Iss. 64, p. 72

Lenco J., Hubalek M., Larsson P., Fucikova A., Brychta M., Macela A., Stulik J.: Proteomics analysis of the *Francisella tularensis* LVS response to iron restriction: induction of the, FEMS microbiology letters, 2007, Blackwell Synergy, Iss. 11, p. 21

Hrstka R., Kročova Z., Cerny J., Vojtesek B., Macela A., Stulik J.: Francisella tularensis LVS resides in MHC II-positive autophagic vacuoles in macrophages, Folia Microbiologica, 2007, Vol. 52,

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms* and/or toxins studied, as well as outdoor studies of biological aerosols.

The study of virulent factors, proteomics and vaccine development of *Francisella tularensis*, the interaction of *F. tularensis* with eukaryotic cells, the study of bioaerosols carrying of *Bacillus subtilis*.

*Including viruses and prions.

Exchange of data on research centres and laboratories [1] - # 3

1. **Name(s) of facility**[2]
   Central Military Health Institute, department Techonin

2. **Responsible public or private organization or company**
   Central Military Health Institute (Ministry of Defence)

3. **Location and postal address**
   Central Military Health Institute, department Techonin, 561 66 Techonin, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   wholly financed by the Ministry of Defence

5. **Number of maximum containment units**[3] **within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BL 2

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Cultivation of microbe (*Francisella tularensis*, vaccine strain LVS) for immunological studies, preparation of monoclonal antibodies and PCR probes

---

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

National biological defence research and development programme Declaration

Is there a national programme to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such a programme would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of the programme.

National biological defence research and development programme

Description

1. State the objectives and funding of the programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

   Polyclonal antibodies preparation for *Francisella tularensis* detection and diagnosis
   Probe preparation for PCR *Francisella tularensis* detection and identification

2. State the total funding for the programme and its source.

   Wholly financed by the Ministry of Defence

3. Are aspects of this programme conducted under contract with industry, academic institutions, or in other non-defence facilities?

   No

4. If yes, what proportion of the total funds for the programme is expended in these contracted or other facilities?

5. Summarize the objectives and research areas of the programme performed by contractors and in other facilities with the funds identified under paragraph 4.

6. Provide a diagram of the organizational structure of the programme and the reporting relationships (include individual facilities participating in the programme).

7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to the national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

National biological defence research and development programme

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?
Central Military Health Institute, department Těchonin

2. Where is it located (include both address and geographical location)?
561 66 Těchonín, WGS 84, E 615553m, N 5546505m

3. Floor area of laboratory areas by containment level:

BL2 145 (sqM) [3 units BL 2]

BL3 0 (sqM)

BL4 0 (sqM)

Total laboratory floor area 145 (sqM)

4. The organizational structure of each facility.

(i) Total number of personnel 14

(ii) Division of personnel:

Military	5
Civilian	9

(iii) Division of personnel by category:

Scientists	5
Engineers	0
Technicians	7
Administration and support staff	2

(iv) List the scientific disciplines represented in the scientific/ engineering staff.

general biology	(3)
clinical biology and chemistry	(1)
general zootechny	(1)

(v) Are contractor staff working in the facility? If so, provide an approximate number.
No

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

Wholly financed by the Ministry of Defence

(vii) What are the funding levels for the following programme areas:

Research (CZK)	1.000.000,-
Development (CZK)	500.000,-
Test and evaluation (CZK)	100.000,-

(viii) Briefly describe the publication policy of the facility:

Results are published in international and national scientific and military journals.

(ix) Provide a list of publicly-available papers and reports resulting from the work during the previous 12 months. (To include authors, titles and full references.)

Pohanka M., Pavliš O., Skládal P.: Diagnosis of tularemia using piezoelectric biosensor technology, Talanta, 2007, Iss. 71, pp 981-985

Pohanka M., Pavliš O., Skládal P.: Rapid characterization of monoclonal antibodies using the piezoelectric immunosenzor; Senzors, 2007, Iss. 7, pp. 341-353

Pavliš O., Kroča M.: Cytometrická analýza in vivo aktivace CD19 buněk na myším modelu, Abstract Collection, FVZ UO Hradec Králové a Vakcinační centrum ISBN 978-80-7231-323-5

Pohanka M., Pavliš O., Skládal P.: Využití piezoelektrických biosenzorů ke stanovení imunoglobulinů, Abstract Collection, FVZ UO Hradec Králové a Vakcinační centrum ISBN 978-80-7231-323-5

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms* and/or toxins studied, as well as outdoor studies of biological aerosols.

Immunological studies of model microorganism (*Francisella tularensis*, vaccine strain LVS) for detection of biological agents

*Including viruses and prions.

Exchange of data on research centres and laboratories[1] - # 4

1. **Name(s) of facility**[2]
   Laboratory for Biological Monitoring and Protection

2. **Responsible public or private organisation or company**
   National Institute for Nuclear, Chemical and Biological Protection, Department of Biological Protection

3. **Location and postal address**
   Pribram - Kamenna 71, 262 31 p. Milin

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   The reported activity is not financed by the Ministry of Defence.
   The Institute is a non-profit organisation established on the basis of the decision made by the chairperson of the State Office for Nuclear Safety.

5. **Number of maximum containment units**[3] **within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   BL – 4 (14 m^2)

6. **If no maximum containment unit, indicate highest level of protection**

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate are:**
   Detection of pathogens by molecular methods, microbiological cultivation, and mass spectrometry. Development, verification and evaluation methods for detection and quantification of biological agents and toxins and protection against them
   This laboratory is used for emergency response assistance for bioterrorism (initial triage and investigation of suspicious packages - primary identification and culture for *Bacillus anthracis*, etc.)
   (microorganisms: *Bacillus anthracis, Yersinia pestis, Francisella tularensis, Brucella species, Salmonella species, Burkholderia mallei, Burkholderia pseudomallei, Chlamydia psitaci, Coxiella burnetii, Rikettsia prowazekii*; toxins: Saxitoxin, Trichothecene toxins, Aflatoxins, Conotoxin, Tetrodotoxin, Microcystin).

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent

Exchange of data on research centres and laboratories[1] - # 5

1. **Name(s) of facility**[2]
   Laboratory of Molecular Biology

2. **Responsible public or private organization or company**
   GENERI BIOTECH, s.r.o

3. **Location and postal address**
   Machkova 587, 500 11 Hradec Kralove

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   The reported activity is partly financed by the Ministry of Defence.

5. **Number of maximum containment units**[3] **within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BL 2

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate:**
   Multiplex system molecular detection of high-risky pathogenic microorganisms that might be used in field - project MOLECDETECTION (QRT PCR: *Bacillus anthracis, Yersinia pestis, Francisella tularensis, Brucella species, Salmonella species, Burkholderia mallei, Burkholderia pseudomallei, Chlamydia psitaci, Coxiella burnetii, Rikettsia prowazekii*)

National biological defence research and development programme Declaration

Is there a national programme to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such a programme would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of the programme.

National biological defence research and development programme

Description

1. State the objectives and funding of the programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

   Multiplex QRT PCR system molecular detection of high-risky pathogenic microorganisms that might be used in field - project MOLEKDETEKCE

2. State the total funding for the programme and its source.

   Partly financed by the Ministry of Defence

3. Are aspects of this programme conducted under contract with industry, academic institutions, or in other non-defence facilities?

   Yes

4. If yes, what proportion of the total funds for the programme is expended in these contracted or other facilities?

Program expense (for 3 years):	CZK 6 310 000
Generi Biotech (for 3 years):	CZK 3 155 000
Ministry of Defence (for 3 years):	CZK 3 155 000

5. Summarize the objectives and research areas of the programme performed by contractors and in other facilities with the funds identified under paragraph 4.

6. Provide a diagram of the organizational structure of the programme and the reporting relationships (include individual facilities participating in the programme).

7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to the national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

National biological defence research and development programme

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?
Laboratory of Molecular Biology, GENERI BIOTECH s.r.o.

2. Where is it located (include both address and geographical location)?
Machkova 587, 500 11 Hradec Kralove

3. Floor area of laboratory areas by containment level:

BL2 138 (sqM)

BL3 0 (sqM)

BL4 0 (sqM)

Total laboratory floor area 145 (sqM)

4. The organizational structure of each facility.

(i) Total number of personnel 15

(ii) Division of personnel:

Military	0
Civilian	15

(iii) Division of personnel by category:

Scientists	9
Engineers	1
Technicians	3
Administration and support staff	2

(iv) List the scientific disciplines represented in the scientific/ engineering staff.
Analytical chemistry, pharmacy, genetics, bioanalysis, molecular biology

(v) Are contractor staff working in the facility? If so, provide an approximate number.
No

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

Partly financed by own sources and partly financed by the Ministry of Defence

(vii) What are the funding levels for the following programme areas:

Research (CZK)	4 055 000
Development (CZK)	2 255 000
Test and evaluation (CZK)	

(viii) Briefly describe the publication policy of the facility:

(ix) Provide a list of publicly-available papers and reports resulting from the work during the previous 12 months. (To include authors, titles and full references.)

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms* and/or toxins studied, as well as outdoor studies of biological aerosols.

Multiplex QRT PCR system molecular detection of high-risky pathogenic microorganisms that might be used in field; each detection run in two steps

*Including viruses and prions.

Exchange of data on research centres and laboratories [1] - # 6

1. **Name(s) of facility** [2]
   Division of Infectious Diseases, Department of Infectious Diseases and Epizootology, Faculty uf Veterinary Medicine

2. **Responsible public or private organization or company**
   University of Veterinary and Pharmaceutical Sciences Brno (the Ministry of Education, Youth and Sports)

3. **Location and postal address**
   Palackého 1/3, 612 42 Brno

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   the Ministry of Education, Youth and Sports

5. **Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BL 3 (total area approx. 40m^2)

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   The laboratory provides research and diagnostic services (*Chlamydia psitaci*, Avian influenza viruses, Newcastle disease virus)

---

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

Exchange of data on research centres and laboratories [1] - # 7

1. **Name(s) of facility** [2]
   National Institute of Public Health; Centre of Epidemiology and Microbiology

2. **Responsible public or private organization or company**
   Ministry of Health of the Czech Republic

3. **Location and postal address**
   Srobarova 48, 100 42 Praha 10, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   The reported activity is wholly financed by the Ministry of Health

5. **Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BL 3 [3 boxes 7,3m^2 + 7,3m^2 + 10,05 m^2] total area approx. 107 m^2

8. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Diagnostic and public health laboratory
   Isolation and identification of *Mycobacterium tuberculosis* (human specimens)
   Revival and cultivation of strains of the Czech National Clollection of Type Cultures
   Cultivation of low-pathogenic strains of Avian influenza viruses
   Investigation of suspicious packages (identification and culture for *Bacillus anthracis*)

---

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

Exchange of data on research centres and laboratories [1] - # 8

1. **Name(s) of facility**[2]
   Bioveta, a.s.

2. **Responsible public or private organization or company**

3. **Location and postal address**
   Komenského 212, 683 23 Ivanovice na Hané, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Fully financed by own sources

5. **Number of maximum containment units**[4] **within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BL 3

Name of laboratory	Area (m^2)
Quality control department	88
Bacterial products production department	134
Viral vaccines production department	80
Sterile pharmaceuticals production department	130
Lyophilisation department	138
Finalisation department	94

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**

Bacteria:

production: cultivation for purposes of growing and production of the bacterial mass for further use (production of preparations, storage of the bacterial strains)
use: activation of the stored freeze dried bacterial culture and cultivation
procurement: purchasing of the needed bacterial strains from both Czech and foreign collections
keeping: storage of the bacterial strains freeze-dried
import: purchasing of the needed bacterial strains from foreign collections
export: export of bacterial vaccines containing live vaccination strains
transport: transport of bacterial vaccines containing live vaccination strains
disposal: inactivation if this is a part of the technological procedure for production of the preparation
inactivation for purposes of disposal (biological waste generated during the production process of the bacterial strains and preparations – control tests, growth properties, determination of the number of CFU etc.)

The following high risk biological agents are used for development, production and control of the veterinary immunopreparations (vaccines, diagnostics).

Bacillus anthracis
Brucella melitensis
Brucella abortus
Brucella ovis
Brucella suis
Burkholderia mallei
Burkholderia pseudomallei
Francisella tularensis
Salmonella typhi

Viruses:
production: cultivation for purposes of growing and production of the viral antigen for further use (production of preparations, storage of the viral strains)
use: activation of the stored viral strain (frozen, freeze dried…)
procurement: purchasing of the needed viral strains from both Czech and foreign collections
keeping: storage of the viral strains freeze-dried or frozen
import: purchasing of the needed viral strains from foreign collections
export: export of the viral vaccines containing live vaccination strains
transport: transport of the viral vaccines containing live vaccination strains
disposal: inactivation this is a part of the technological procedure for production of the preparation
inactivation for purposes of disposal (biological waste generated during cultivation – control tests, growth properties, determination of the titre etc.)
The following high risk biological agents are used for development, production and control of the veterinary immunopreparations.

Rabies virus
Aujeszky's disease virus
Avian influenza virus
Classical swine fever virus
Avian Newcastle disease virus
Teschen disease virus (porcine encephalomyelitis virus)

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

Exchange of data on research centres and laboratories [1] - # 9

1. **Name(s) of facility** [2]
   State Veterinary Institute Prague

2. **Responsible public or private organization or company**
   public organization (Ministry of Agriculture)

3. **Location and postal address**
   Sidlistni 136/24, 165 03 Praha 6 – Lysolaje, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Financed by the Ministry of Agriculture

5. **Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   BL 4 Lab – FMD (area approx. 75 m^2)

6. **If no maximum containment unit, indicate highest level of protection**
   BSL 3 Lab – AI (area approx. 89 m^2)

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Laboratory diagnostics – animal viruses and bacteria
   aflatoxins, trichotecens

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

Background information on outbreaks of reportable infectious diseases #1 - human

Disease	Number of cases per year				
	2003	2004	2005	2006	2007
Listeriosis*	13	16	15	78	51
Salmonellosis **	1.822	1.788	1.034	1.272	766
Shigellosis**	152	61	78	116	62
Viral Hepatitis A**	26	0	163	22	22

a. * number of cases
b. ** number of cases in outbreaks

Source of data: Epidat, Information system of notifiable diseases in the Czech Republic, Department of Biostatistics and Informatics, National Institute for Public Health, Prague, 14/02/2008

Background information on outbreaks of reportable infectious diseases #2 - animals

Disease	Number of cases per year				
	2003	2004	2005	2006	2007
Rabies	0	0	1[+]	0	0
Bluetongue virus	0	0	0	0	1
Avian influenza virus	0	0	0	12	1

\+ 1 case of bat rabies

C. Encouragement of publication of results and promotion of use of knowledge

List of the most important publication which appeared during the year 2007:

Malcova-M, Hradecka-H, Karpiskova-R, Rychlik-I.: Biofilm formation in field strains of *Salmonella enterica* serovar *Typhimurium*: Identification of a new colony morphology type and the role of SGI1 in biofilm formation. ; Veterinary microbiology Amsterdam, {Vet-Microbiol}, 23 Dec 2007 (epub: 23 Dec 2007), ISSN: 0378-1135.

Literák I., Vanko R., Dolejská M., Cízek A., Karpísková R..: Antibiotic resistant *Escherichia coli* and *Salmonella* in Russian rooks (*Corvus frugilegus*) wintering in the Czech Republic. ; Letters in applied microbiology, {Lett-Appl-Microbiol}, Dec 2007 (epub: 04 Oct 2007), vol. 45, no. 6, p. 616-21, ISSN: 0266-8254.

Ruzek D ., Piskunova N., Zampachová E.: High variability in viral load in cerebrospinal fluid from patients with herpes simplex and varicella-zoster infections of the central nervous system.; Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, {Clin-Microbiol-Infect}, Dec 2007 (epub: 22 Oct 2007), vol. 13, no. 12, p. 1217-9, ISSN: 1198-743X.

Holada K., Simak J., Brown P., Vostal J.G.: Divergent expression of cellular prion protein on blood cells of human and nonhuman primates.; Transfusion, {Transfusion}, Dec 2007 (epub: 21 Aug 2007), vol. 47, no. 12, p. 2223-32, ISSN: 0041-1132.

Dolejska M., Cizek A., Literak I..: High prevalence of antimicrobial-resistant genes and integrons in *Escherichia coli* isolates from Black-headed Gulls in the Czech Republic.; Journal of applied microbiology, {J-Appl-Microbiol}, Jul 2007, vol. 103, no. 1, p. 11-9, ISSN: 1364-5072.

Ruzek D., Stastná H., Kopecký J., Golovljova I., Grubhoffer L.: Rapid subtyping of tick-borne encephalitis virus isolates using multiplex RT-PCR.; Journal of virological methods, {J-Virol-Methods}, Sep 2007 (epub: 04 Jun 2007), vol. 144, no. 1-2, p. 133-7, ISSN: 0166-0934.

Knejzlík Z., Smékalová Z., Ruml T., Sakalian M.: Multimerization of the p12 domain is necessary for Mason-Pfizer monkey virus Gag assembly in vitro.; Virology, {Virology}, 1 Sep 2007 (epub: 09 May 2007), vol. 365, no. 2, p. 260-70, ISSN: 0042-6822.

Nagy A., Machova J., Hornickova J., Tomci M., Nagl I., Horyna B., Holko I.: Highly pathogenic avian influenza virus subtype H5N1 in Mute swans in the Czech Republic; Veterinary microbiology, {Vet-Microbiol}, 25 Feb 2007 (epub: 12 Oct 2006), vol. 120, no. 1-2, p. 9-16, ISSN: 0378-1135.

Tcheremenskaia O., Marucci G., De-Petris S., Ruggeri F.M., Dovecar D., Sternak S.L., Matyasova I., Dhimolea M.K., Mladenova Z., Fiore L.: Molecular epidemiology of rotavirus in Central and Southeastern Europe; Journal of clinical microbiology, {J-Clin-Microbiol}, Jul 2007 (epub: 16 May 2007), vol. 45, no. 7, p. 2197-204, ISSN: 0095-1137.

Pohanka M., Jun D., Kuca K.: Mycotoxin assays using biosensor technology: a review**;** Drug and chemical toxicology, {Drug-Chem-Toxicol}, 2007, vol. 30, no. 3, p. 253-61, 48 refs, ISSN: 0148-0545.

Active promotion of contacts

Planed international conferences, symposia, seminars and other similar forums for exchange

a) name of the conference, etc.
International Workshop on Biological Crises Management

arranging organization(s), etc.
Centre of Advanced Studies, Faculty of Military Health Sciences, University of Defence, Hradec Kralove

time September 29-30, 2008

place Hradec Kralove

main subject(s) for the conference, etc.
Biological crisis management, risk assessment, medical countermeasures

conditions for participation

point of contact for further information, registration, etc.
http://www.pmfhk.cz/Prechodne/Workshop_Macela/workshop1.htm ; amacela@pmfhk.cz

b) name of the conference, etc.
International Workshop on Biomedical Research

arranging organization(s), etc.
Institute of Molecular Pathology**,** Faculty of Military Health Sciences, University of Defence, Hradec Kralove; Czech Immunological Society

time 28th April – 1st May 2008

place Valtice

main subject(s) for the conference, etc.
Host-pathogen Interaction, Molecular aspects of carcinogenesis

conditions for participation
registration fee CZK 1000,- (EUR 33,-)

point of contact for further information, registration, etc.
krocova@pmfhk.cz; klimentova@pmfhk.cz

c) name of the conference, etc.
XVII Conference of Young Microbiologists Tomasek Days

arranging organization(s), etc.
the Institute for Microbiology of the Faculty of Medicine of Masaryk University in Brno and St. Anna Faculty Hospital in Brno

time June 5–6, 2008

place Brno, Czech Republic

main subject(s) for the conference, etc.
general microbiology, factors of pathogenicity, epidemiology and epizootology

point of contact for further information, registration, etc.
tomdny@fnusa.cz

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulation	Other measures	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other microbiological agents, or toxins, weapons, equipment and means of delivery specified in Article I	YES/[redacted]	YES/[redacted]	[redacted]/NO	[redacted]/NO
(b) Exports of micro-organisms* and toxins	YES/[redacted]	YES/[redacted]	[redacted]/NO	[redacted]/NO
(c) Imports of micro-organisms* and toxins	YES/[redacted]	YES/[redacted]	[redacted]/NO	[redacted]/NO

* Micro-organisms pathogenic to man, animals and plants in accordance with the Convention

Declaration of vaccine production facility - #1

1. **Name of facility:**

   Baxter BioScience s.r.o.

2. **Location (mailing address):**

   Jevany-Bohumil 138, 281 63 Kostelec nad Černými lesy

3. **General description of the types of diseases covered:**

   list of products manufactured: Influenza vaccine/s (whole virion) against flu (human); Cell culture preparation, cultivation of influenza viruses, harvest, inactivation, purification, transfer to facility in Austria for final filling

   list of products manufactured and distributed: none

   list of products on which R&D is carried out: none

   list of products distributed: none

Declaration of vaccine production facility - # 2

1. **Name of facility:**

   Sevapharma a.s.

2. **Location (mailing address):**

   Korunní 108, 101 03 Praha 10, Czech Republic

3. **General description of the types of diseases covered:**

   Production of vaccines, immunomodulators, allergens and diagnostics (microbial, viral, immunochemical and other).

viral vaccines:	live vaccine against measles, mumps and rubella
bacterial vaccines:	vaccine against tetanus multi-component staphylococcus toxoid anti-staphylococcus phage lyzate for topical application

Declaration of vaccine production facility- # 3

1. **Name of facility:**

   Bioveta, a.s.

2. **Location (mailing address):**

   Komenského 212, 683 23 Ivanovice na Hané, Czech Republic

3. **General description of the types of diseases covered:**

   Manufacturer of: veterinary vaccines for use in animals
   in vitro diagnostic test kits for diagnosis of animal diseases
   diagnostic antigens
   positive diagnostic sera
   antisera and globulins for use in animals

Production of veterinary vaccines:

Bacterial

Vaccine against anthrax, Inactivated vaccine against Lyme disease, Inactivated vaccine against canine and fur animal leptospirosis, Inactivated vaccine against mycotic disease caused by Microsporum canis in dogs, Vaccine against tetanus, Live vaccine against red murrain in pigs, Inactivated vaccine against porcine erysipelas, Vaccine against enteric coli infections in suckling piglets and against porcine erysipelas, inactivated, Vaccine against enteric coli-infections of suckling piglets, Vaccine against leptospirosis in cattle and horses, Vaccine against bovine infectious keratoconjunctivitis, inactivated, Rabbit pasteurellosis vaccine inactivated, Vaccine against porcine pleuropneumonia, Pig rhinitis vaccine with dermonecrotoxical toxoid, Vaccine against salmonellosis in poultry, attenuated, Avirulent vaccine against bovine trichophytosis, Lyophilized vaccine against bovine trichophytosis, Vaccine against horse trichophytosis, Vaccine against trichophytosis in animals with fur

Viral

Inactivated vaccine against coronary viral disease in dogs, Live vaccine against distemper, infectious hepatitis, infectious laryngotracheitis, parvovirosis and parainfluenza in dogs, Live vaccine against distemper and parvovirosis in dogs, Live vaccine against parvovirosis in dogs, Vaccine against rabies, inactivated, Vaccine against panleucopenia, calicivirus and herpesvirus infection of cats, The vaccine against feline panleukopenia, herpesviral and caliciviral infection, and rabies of cats, Inactivated vaccine against equine influenza, Vaccine against IBR inactivated, Vaccine against rabies intended for oral immunization in foxes, Live vaccine against myxomatosis, MXT, Live vaccine against infectious bronchitis in poultry, lyophilised, Live vaccine against infectious bursitis in poutry (Gumboro disease), lyophilized, Duck infectious hepatitis inactivated vaccine, Vaccine against Parvovirus Disease in Goslings, Inactivated, Live vaccine against Newcastle disease in poultry, lyophilized, Inactivated vaccine against the egg drop syndrome, Inactivated vaccine against Newcastle disease and infectious bursitis in poultry, Vaccine against

porcine parvovirosis, inactivated, Vaccine against swine fever TVM-1, Vaccine against pest in rabbits, Vaccine against pest and myxomatosis in rabbits,

Combined (bacterial and viral)
Vaccine against canine distemper, infectious hepatitis, infectious laryngotracheitis, parvovirus, parainfluenza and leptospirosis in dogs and furry animals, Vaccine against canine distemper, infectious hepatitis, infectious laryngotracheitis, parvovirus, parainfluenza, leptospirosis and rabies in dogs and furry animals, Inactivated vaccine against canine and fur animal leptospirosis and rabies, Live vaccine against red murrain and pest in pigs, Inactivated vaccine against equine influenza and tetanus, Vaccine against rota, corona and coli infections in newborn calves, inactivated, Vaccine against parvovirosis and swine erysipelas, Vaccine against rotaviral and enteral coliinfections in pigs

Diagnostic test kits
Kit for diagnostics of leucosis in cattle by immunodiffusion test, Set for serological diagnostics of brucellosis using the slow agglutination, Set for serological diagnostics of brucellosis using the quick agglutination, Set for diagnostics of brucellosis – RBT, Set for diagnostics of brucellosis using the complement bond reaction (CBR), Set for diagnostics of dourine using the complement bond reaction (CBR), Set for diagnostics of chlamydiosis using the complement bond reaction (CBR), Set for diagnostics of listeriosis by slow and quick agglutinations, Kit for diagnostics of paratuberculosis using the complement bond reaction (CBR), Set for diagnostics of pullorosis using the slow agglutination, Set for diagnostics of pullorosis using the quick agglutination, Set for diagnostics of anthrax using by precipitation method, Set for diagnostics of tularemia, Set for diagnostics of glanders using the complement bond reaction (CBR),

Declaration of vaccine production facility - #4

1. **Name of facility:**

   Dyntec, s.r.o.

2. **Location (mailing address):**

   Pražská 328, 411 55 Terezín, Czech Republic

3. **General description of the types of diseases covered:**

   Human vaccine: per-oral vaccine against bacterial diarrhoea

   Veterinary products:
   - vaccines against *Actinobacillus pleuropneumoniae* and edema disease of pigs
   - vaccines against parvovirosis and erysipelas of pigs
   - vaccines against distemper, infectious hepatitis, infectious laryngotracheitis, parvovirosis, parainfluenza and leptospira icterohaemorrhagiae, grippotyphosa and sejroe of dogs
   - vaccine for the prevention of rabies in wild carnivorous animals and stray dogs
   - vaccines against myxomatosis and viral hemorrhagic disease of rabbits

Declaration of vaccine production facility - #5

1. **Name of facility:**
   BIOPHARM, Research Institute of Biopharmacy and Veterinary Drugs

2. **Location (mailing address):**
   Pohori-Chotun, 254 49 Jilove u Prahy

3. **General description of the types of diseases covered:**
   Vaccine against coccidiosis in poultry